Evidence map›Paper›PMID 39050797›Full record

ArticleDrug design, development and therapy2024

The Discovery of GIT1/β-Pix Inhibitors: Virtual Screening and Biological Evaluation of New Small-molecule Compounds with Anti-invasion Effect in Gastrointestinal Neoplasms.

Chenkun Wang, Jing Gu, Hongwei Li, Bo Zhao, Tao Yu, Chun-Ling Guo, Mouxin Huang, Weiwei Jiang, Qin Ouyang

Abstract read
In one paragraph

Article in Drug design, development and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chenkun Wang *Department of Pharmacy, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, People's Republic of China.
Jing Gu *Department of Medicinal Chemistry, College of Pharmacy, Third Military Medical University, Chongqing, People's Republic of China.
Hongwei Li *Department of Medicinal Chemistry, College of Pharmacy, Third Military Medical University, Chongqing, People's Republic of China.
Bo ZhaoDepartment of Medicinal Chemistry, College of Pharmacy, Third Military Medical University, Chongqing, People's Republic of China.
Tao YuDepartment of Pharmacy, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, People's Republic of China.
Chun-Ling GuoDepartment of Medicinal Chemistry, College of Pharmacy, Third Military Medical University, Chongqing, People's Republic of China.
Mouxin HuangDepartment of Medicinal Chemistry, College of Pharmacy, Third Military Medical University, Chongqing, People's Republic of China.
Weiwei JiangDepartment of Pharmacy, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, People's Republic of China.
Qin OuyangDepartment of Medicinal Chemistry, College of Pharmacy, Third Military Medical University, Chongqing, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objective: GIT1 (G-protein-coupled receptor kinase interacting protein-1) has been found to be highly related with cancer cell invasion and metastasis in many cancer types. β-Pix (p21-activated kinase-interacting exchange factor) is one of the proteins that interact with GIT1. Targeting GIT1/β-Pix complex might be a potential therapeutic strategy for interfering cancer metastasis. However, at present, no well-recognized small-molecule inhibitor targeting GIT1/β-Pix is available. Thus, we aim to discover novel GIT1/β-Pix inhibitors with simple scaffold, high activity and low toxicity to develop new therapeutic strategies to restrain cancer metastasis. Methods: GIT1/β-Pix inhibitors were identified from Results: We selected the top 50 compounds from the Conclusion: We discovered a new GIT1/β-Pix inhibitor (17302836) against gastrointestinal cancer invasion and metastasis. This study provides a promising candidate for developing new GIT1/β-Pix inhibitors for tumor treatment.

Indexed as

Antineoplastic AgentsCell Cycle ProteinsDrug Screening Assays, AntitumorAdaptor Proteins, Signal TransducingCell MovementCell ProliferationDose-Response Relationship, DrugDrug DiscoveryDrug Evaluation, PreclinicalGastrointestinal NeoplasmsHumansMolecular StructureNeoplasm InvasivenessRho Guanine Nucleotide Exchange FactorsSmall Molecule LibrariesStructure-Activity RelationshipAdaptor Proteins, Signal TransducingAntineoplastic AgentsCell Cycle ProteinsGIT1 protein, humanRho Guanine Nucleotide Exchange FactorsSmall Molecule Librariesgastrointestinal cancersGIT1hit discoveryinvasionvirtual screeningβ-Pix

Identifiers

PMID39050797
PMCPMC11268723

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.